Bone Morphogenetic Protein‐2 Decreases MicroRNA‐30b and MicroRNA‐30c to Promote Vascular Smooth Muscle Cell Calcification

Background Vascular calcification resembles bone formation and involves vascular smooth muscle cell (SMC) transition to an osteoblast‐like phenotype to express Runx2, a master osteoblast transcription factor. One possible mechanism by which Runx2 protein expression is induced is downregulation of in...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Heart Association 2012-12, Vol.1 (6), p.e003905-n/a
Main Authors: Balderman, Joshua A. F., Lee, Hae‐Young, Mahoney, Christopher E., Handy, Diane E., White, Kevin, Annis, Sofia, Lebeche, Djamel, Hajjar, Roger J., Loscalzo, Joseph, Leopold, Jane A.
Format: Article
Language:English
Subjects:
Bone Morphogenetic Protein 2 - pharmacology
Cells, Cultured
Core Binding Factor Alpha 1 Subunit - drug effects
Core Binding Factor Alpha 1 Subunit - genetics
Core Binding Factor Alpha 1 Subunit - metabolism
Coronary Artery Disease - etiology
Coronary Artery Disease - metabolism
Down-Regulation
Humans
microRNA
MicroRNAs - drug effects
MicroRNAs - genetics
MicroRNAs - metabolism
MicroRNAs - physiology
Muscle, Smooth, Vascular - drug effects
Muscle, Smooth, Vascular - metabolism
Myocytes, Smooth Muscle - drug effects
Myocytes, Smooth Muscle - metabolism
Original Research
Real-Time Polymerase Chain Reaction
Runx2
smooth muscle cells
vascular calcification
Vascular Calcification - etiology
Vascular Calcification - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Vascular calcification resembles bone formation and involves vascular smooth muscle cell (SMC) transition to an osteoblast‐like phenotype to express Runx2, a master osteoblast transcription factor. One possible mechanism by which Runx2 protein expression is induced is downregulation of inhibitory microRNAs (miR). Methods and Results Human coronary artery SMCs (CASMCs) treated with bone morphogenetic protein‐2 (BMP‐2; 100 ng/mL) demonstrated a 1.7‐fold (P
ISSN:2047-9980
2047-9980
DOI:10.1161/JAHA.112.003905